Triphasic Osteochondral Scaffold for the Treatment of the OCD of the Knee: Observational Study

Inclusion Criteria - Male or female patients, aged 15-40 years; - Single symptomatic osteochondral injury from OCD classified as ICRS OCD III or IV at the level of the femoral condyles; - Failure of conservative treatment - Lesion size between 1 and 10 cm2; - BMI ≤ 30; - Ability and consent of patients to actively participate in the rehabilitation protocol and clinical and radiological follow-up. Who Should NOT Join This Trial: - -Additional grade III or IV cartilage injury on the knee being treated; - Advanced osteoarthritis - Systemic or localized infection - Systemic (e.g. rheumatoid arthritis) or local (e.g. synovitis) inflammatory diseases and cardiovascular diseases - Immune system disorders - Degenerative or vascular bone pathology (e.g. osteonecrosis) - Coagulation disorders - Systemic conditions that alter wound healing - Established allergy to equine collagen and calcium phosphate salts - Presence of ligamentous/patellofemoral instability/malignment, varus or valgus malalignment ≤ 3° that cannot be treated/corrected simultaneously; - Previous tendon repair, ligamentous reconstruction, or realignment procedures within the past 12 months; - Presence of any known human weakened immune system virus, hepatitis, syphilis, malignant neoplasms and ongoing anti-neoplastic chemotherapy and radiation treatment; Uncontrolled diabetes; Uncontrolled thyroid function changes; Uncontrolled metabolic disorders; Renal disease and hypercalcemia - Uncooperative patients, including those with a history of alcohol and drug abuse; Participation in another clinical trial or medical device trial that clinically interferes with the present pilot study; - Incapacitated patients; - Pregnant or lactating women. In particular, in the case of a suspected pregnancy in a patient of childbearing age, this will be excluded by serological testing (hCG). Always talk to your doctor about whether this trial is right for you.